NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma

Massimo CorradiUniversity of Parma, Department of Clinical and Experimental Medicine, Parma, Italy+0039 0521 033098; +0039 0521 033099; [email protected]

, MD,

Henry ChrystynUniversity of Huddersfield, School of Applied Sciences, Huddersfield, UK

, PhD FHEA FRPharmS,

Borja G CosioHospital Universitario Son Espases, Department of Respiratory Medicine, IDISMA, Ciberes, Palma de Mallorca, Spain

, MD,

Michal PirozynskiCenter of Postgraduate Medical Education, Department of Anesthesiology and Critical Care Medicine, Warsaw, Poland;Center of Postgraduate Medical Education, Department of Allergology and Pulmonology, Warsaw, Poland

, MD,

Stelios LoukidesUniversity of Athens Medical School, Respiratory Medicine Department, Athens, Greece

, MD,

Renaud LouisUniversity of Liege, Department of Respiratory Medicine, CHU Liege, GIGAI3 research group, liege, Belgium

, MD,

Monica SpinolaChiesi Farmaceutici, Parma, Italy

, PhD &

Omar S UsmaniNational Heart and Lung Institute, Imperial College London & Royal Brompton Hospital, London, UK

, MD show all

NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date